A key mediator, PTX3, of IKK/IκB/NF-κB exacerbates human umbilical vein endothelial cell injury and dysfunction

Int J Clin Exp Pathol. 2014 Oct 15;7(11):7699-707. eCollection 2014.

Abstract

Objective: This study was performed to investigate PTX3-mediated iNOS expression and IKK/IκB/NF-κB activation in PA-induced atherosclerotic HUVECs injury model.

Methods: The cell viability was detected by the CCK8 assay. The cell apoptosis was assessed by annexin V-PI double-labeling staining. Expression of genes and proteins were analyzed by real-time PCR and western blotting respectively. Cells were transfected with siRNAs as a gene silencing methods.

Results: PA induced cell apoptosis in human umbilical vein endothelial cells in a time and dose-dependent manner. PA also induced upregulation expression of PTX3. TPCA-1, an inhibitor of IKK-2, could suppress the expression of PTX3 and phospho-IκB-α in PA-induced endothelial dysfunction cell model. We also found that transfection of cells with PTX3 siRNA reduced the expression of iNOS and NO, and protected PA-induced cell apoptosis in HUVECs.

Conclusions: PTX3 could exacerbate endothelial dysfunction, at least partially, through IKK/IκB/NF-κB activation and overexpression of iNOS and NO, and advance the development of atherosclerosis.

Keywords: HUVECs; NF-κB; PTX3; atherosclerosis; iNOS.

MeSH terms

  • Apoptosis / drug effects
  • Atherosclerosis / metabolism
  • Atherosclerosis / pathology
  • C-Reactive Protein / genetics
  • C-Reactive Protein / metabolism*
  • Cell Survival / drug effects
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism*
  • Human Umbilical Vein Endothelial Cells / pathology
  • Humans
  • I-kappa B Proteins / metabolism*
  • NF-KappaB Inhibitor alpha
  • NF-kappa B / metabolism*
  • Nitric Oxide / metabolism
  • Nitric Oxide Synthase Type II / metabolism
  • Palmitic Acid / pharmacology
  • Serum Amyloid P-Component / genetics
  • Serum Amyloid P-Component / metabolism*
  • Signal Transduction / drug effects*

Substances

  • I-kappa B Proteins
  • NF-kappa B
  • NFKBIA protein, human
  • Serum Amyloid P-Component
  • NF-KappaB Inhibitor alpha
  • PTX3 protein
  • Palmitic Acid
  • Nitric Oxide
  • C-Reactive Protein
  • Nitric Oxide Synthase Type II